Phase 2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeated Administrations Over 4 Weeks of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis

Trial Profile

Phase 2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeated Administrations Over 4 Weeks of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs PRS 080 (Primary)
  • Indications Iron deficiency anaemia
  • Focus Adverse reactions
  • Sponsors Pieris Pharmaceuticals
  • Most Recent Events

    • 09 Mar 2018 According to a Pharmaceuticals media release, results from the study are expected in the second half of 2018.
    • 27 Oct 2017 Status changed from planning to recruiting.
    • 09 Aug 2017 According to a Pharmaceuticals media release, the company is planning filing of separate clinical trial applications with the German and Czech Republic regulatory authorities to conduct this trial during this quarter.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top